BioMarin Pharmaceutical (NASDAQ:BMRN) Announces FY 2026 Earnings Guidance

BioMarin Pharmaceutical (NASDAQ:BMRN) updated its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.800-3.100 for the period, compared to the consensus EPS estimate of 3.320. The company issued revenue guidance of $3.8 billion-$3.9 billion, compared to the consensus revenue estimate of $3.9 billion.

BioMarin Pharmaceutical Price Performance

BMRN opened at $57.44 on Tuesday. BioMarin Pharmaceutical has a 1 year low of $49.26 and a 1 year high of $70.98. The company’s 50 day simple moving average is $60.43 and its 200 day simple moving average is $58.46. The stock has a market capitalization of $11.12 billion, a PE ratio of 33.33, a P/E/G ratio of 0.61 and a beta of 0.22. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39.

BioMarin Pharmaceutical (NASDAQ:BMRN) last issued its quarterly earnings results on Monday, November 2nd. The biotechnology company reported $0.23 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.31. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the prior year, the business posted $0.12 earnings per share. BioMarin Pharmaceutical’s revenue for the quarter was up 32.0% compared to the same quarter last year. As a group, sell-side analysts expect that BioMarin Pharmaceutical will post 2.59 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. UBS Group began coverage on BioMarin Pharmaceutical in a research report on Thursday, October 15th. They set a “buy” rating and a $88.00 price target for the company. Oppenheimer restated an “outperform” rating on shares of BioMarin Pharmaceutical in a report on Tuesday. Stifel Nicolaus reduced their price objective on BioMarin Pharmaceutical from $70.00 to $66.00 and set a “hold” rating on the stock in a research note on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $86.00 target price on shares of BioMarin Pharmaceutical in a report on Tuesday, October 20th. Finally, Morgan Stanley dropped their target price on shares of BioMarin Pharmaceutical from $124.00 to $122.00 and set an “overweight” rating for the company in a research report on Wednesday, October 21st. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $88.30.

BioMarin Pharmaceutical News Roundup

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BioMarin reported third-quarter revenue of $1.025 billion, up 32% year over year and in line with estimates. Growth was led by a 44% increase in metabolic-condition revenue and a 12% increase in skeletal-condition revenue. Adjusted earnings of $0.23 per share significantly exceeded consensus expectations for a loss. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Positive Sentiment: The company added a new investigational Fabry-disease asset to its clinical portfolio, broadening its rare-disease pipeline. Analysts described the recent setback as timing-related and maintained a constructive long-term view; Citi reiterated a Buy rating with projected upside. BioMarin’s Timing-Related Setback Masks Long-Term Growth Potential
• Positive Sentiment: BioMarin said VOXZOGO for hypochondroplasia has a May 30, 2027 PDUFA action date, providing a potential future growth catalyst in skeletal conditions. BioMarin Reports Third Quarter 2026 Financial and Operating Results
• Neutral Sentiment: Several valuation analyses suggested BMRN may be undervalued—one estimated approximately 21% potential upside—although those assessments depend on the company restoring execution and meeting longer-term growth expectations. BioMarin Pharmaceutical Could Be 21% Undervalued
• Negative Sentiment: BioMarin lowered its 2026 guidance, citing uncertainty over order timing and the impact of two acquired in-process research and development charges. Although the quarterly revenue result was on target, the reduced full-year sales outlook is the main reason investors remain cautious. BioMarin Q3 Earnings and Lowered 2026 Guidance

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.